| Latest Targeted Genetics News Headlines |
| Date | Time | Source | |
| 06/12/2008 | 1:00AM | PRNUS | Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation... More...>> |
| 05/30/2008 | 5:46PM | PRNUS | Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Trial Demonstrates Safety and Preliminary Efficacy and Supports Further Clinical Development of tgAAC94
BOSTON and SEATTLE, May 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) issued a news release earlier today, entitled "Targeted Genetics Reports Additional Data From Inflammatory Arthritis... More...>> |
| 12/03/2007 | 4:30PM | PRNUS | Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflamma
SEATTLE, Dec. 3 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) today reported on the National Institutes of Health (NIH) Recombinant DNA Advisory Committee's (RAC) assessment of the previously reported fatal serious adverse event (SAE) in the Phase I/II trial of tgAAC94 for inflammatory arthritis.
The... More...>> |
| 09/17/2007 | 5:12PM | PRNUS | Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Ar
SEATTLE, Sept. 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) today reported on the public hearing conducted by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC), which reviewed the serious adverse event reported by Targeted Genetics surrounding the death of a... More...>> |
| 12/07/2005 | 9:00AM | PRNUS | Celladon Secures $30 Million in Series B Financing
Funding Will Support Clinical Development of Heart Failure Product
LA JOLLA, Calif., Dec. 7 /PRNewswire/ -- Celladon Corporation, a biotechnology company developing treatments for heart failure and other cardiovascular diseases, announced today that it had raised $30 million in a Series B venture financing. The funding... More...>> |
| 10/04/2005 | 7:43AM | PRNUS | Sirna Therapeutics Granted Broad Patent Covering siRNAs Targeting Huntington's Disease
Patent Strengthens Sirna's On-Going Drug Discovery and Development Efforts
SAN FRANCISCO, Oct. 4 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (NASDAQ:RNAI) the leading clinical-stage RNAi therapeutics company, announced today that the Australian Patent Office has issued a broad patent covering vector expressed... More...>> |
| 08/30/2005 | 7:30AM | PRNUS | Targeted Genetics Announces Issuance of Additional Adeno-Associated Virus (AAV) Vector Technology Patent
SEATTLE, Aug. 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) today announced the issuance of an additional patent related to the Company's adeno-associated virus (AAV) vector technology. U.S. patent #6,936,466, titled "Transcriptionally Activated AAV Inverted Terminal Repeats (ITRs) for Use... More...>> |
| 08/22/2005 | 4:30PM | PRNUS | Targeted Genetics Announces Todd E. Simpson to Step Down as Chief Financial Officer
David Poston to be named as Acting CFO
SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) announced today that Todd E. Simpson, its Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Secretary will leave October 3, 2005 to accept a position with another... More...>> |
| 08/16/2005 | 7:30AM | PRNUS | Targeted Genetics Announces Appointment of Roger L. Hawley, an 18 Year Pharmaceuticals Industry Veteran, to Its Board of Directo
SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) announced today that it has appointed Roger L. Hawley to its board of directors.
Mr. Hawley brings over 18 years of expertise in the pharmaceuticals industry coupled with broad sales, marketing, business development and financial... More...>> |
| 08/02/2005 | 7:30AM | PRNUS | Targeted Genetics Strengthens Intellectual Property for AAV Vector Manufacturing
Targeted Genetics Strengthens Intellectual Property for AAV Vector Manufacturing
SEATTLE, Aug. 2 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (NASDAQ:TGEN) today announced the issuance of a patent covering additional approaches to manufacturing AAV (adeno-associated virus) vectors. The patent, U.S. No. 6,924,128... More...>> |
| 07/28/2005 | 7:30AM | PRNUS | Targeted Genetics Reports Second Quarter Financial Results
Targeted Genetics Reports Second Quarter Financial Results
SEATTLE, July 28 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) today announced its financial results for its second quarter
ended June 30, 2005. As previously announced, the Company will hold a
conference call with analysts at 10:30... More...>> |
| 07/26/2005 | 8:04AM | PRNUS | Targeted Genetics Announces Preliminary Results of Phase I Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
Targeted Genetics Announces Preliminary Results of Phase I
Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
- Results Demonstrate Safety and Support Continued Study of tgAAC94 in
Conjunction With TNF-alpha Antagonists in Inflammatory Arthritis -
SEATTLE, July 26 /PRNewswire-FirstCall/ -- Targeted Genetics... More...>> |
| 07/20/2005 | 7:30AM | PRNUS | Targeted Genetics to Release Financial Results and Host Webcast on Thursday, July 28, 2005
Targeted Genetics to Release Financial Results and Host Webcast
on Thursday, July 28, 2005
SEATTLE, July 20 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) will report its second quarter 2005 financial results on
Thursday, July 28, 2005, before the open of financial markets. Following the
announcement... More...>> |
| 06/03/2005 | 8:00AM | PRNUS | Targeted Genetics' Collaborators Present Preclinical Data on AAV Technology and Inflammatory Disease at the 8th Annual Meeting o
Targeted Genetics' Collaborators Present Preclinical Data on AAV
Technology and Inflammatory Disease at the 8th Annual Meeting of the American
Society Of Gene Therapy
ST. LOUIS and SEATTLE, June 3 /PRNewswire-FirstCall/ -- Targeted Genetics
Corporation (NASDAQ:TGEN) announces that its academic collaborators will
present... More...>> |
| 06/02/2005 | 11:08AM | PRNUS | Targeted Genetics' Collaborators Present Preclinical Data in Huntington's Disease and AAV Expression of Large Proteins at the 8t
Targeted Genetics' Collaborators Present Preclinical Data in
Huntington's Disease and AAV Expression of Large Proteins at the 8th Annual
Meeting of the American Society of Gene Therapy
Presentations Demonstrate Broad Potential of Company's AAV Technology
ST. LOUIS and SEATTLE, June 2 /PRNewswire-FirstCall/ -- Targeted... More...>> |
| 06/02/2005 | 9:01AM | PRNUS | Celladon Announces Successful Preclinical Trials in Congestive Heart Failure
Celladon Announces Successful Preclinical Trials in Congestive
Heart Failure
- Celladon's Collaborators Present Large Animal Trial Results at the American
Society of Gene Therapy Conference in St. Louis, MO -
LA JOLLA, Calif., June 2 /PRNewswire/ -- Celladon Corporation announced today
that its collaborators presented... More...>> |
| 05/26/2005 | 8:15AM | PRNUS | Targeted Genetics to Present Data on Several Programs at the 8th Annual Meeting of the American Society of Gene Therapy
Targeted Genetics to Present Data on Several Programs at the 8th
Annual Meeting of the American Society of Gene Therapy
- Presentations Demonstrate Broad Potential of Company's AAV Technology -
SEATTLE, May 26 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation's
(NASDAQ:TGEN) technology assets will be highlighted... More...>> |
| 05/26/2005 | 8:00AM | PRNUS | New Patent Covers Targeted Genetics' Approach to Increase Carrying Capacity of AAV Vectors
New Patent Covers Targeted Genetics' Approach to Increase
Carrying Capacity of AAV Vectors
SEATTLE, May 26 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) today announced the issuance of another patent related to the
Company's leading adeno-associated virus (AAV) technology platform. U.S.
patent... More...>> |
| 05/17/2005 | 8:00AM | PRNUS | Targeted Genetics Expands AAV Vector Patent Portfolio
Targeted Genetics Expands AAV Vector Patent Portfolio
SEATTLE, May 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) today announced the issuance of an additional patent related to
its adeno-associated virus (AAV) vector technology. U.S. patent #6,893,865,
titled "Methods, Compositions and Cells... More...>> |
| 05/11/2005 | 8:01AM | PRNUS | Targeted Genetics Announces New Patent for Hyperlipidemia
Targeted Genetics Announces New Patent for Hyperlipidemia
Seattle, Wash., May 11 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) announced today issuance of U.S. patent #6,887,463, entitled,
"Methods and Compositions for Gene Therapy for the Treatment of Defects in
Lipoprotein Metabolism." This... More...>> |